text
stringlengths 1
711
|
|---|
(42)
|
(2)
|
31
|
66
|
(136)
|
(20)
|
78
|
12
|
(150)
|
(100)
|
(50)
|
-
|
50
|
100
|
150
|
KENVUE BAYER AG SANOFI PRIVATE LABEL HALEON
|
4W 13W 52W
|
Source: NielsenIQ, J.P. Morgan
|
Figure 99: Allergy - U.S. Volume Share
|
For Periods Ending 5/06/23, YOY (bps)
|
(64)
|
16
|
(30)
|
85
|
33
|
(53)
|
(15)
|
(30)
|
109
|
31
|
(63)
|
(30) (28)
|
68
|
13
|
(80)
|
(60)
|
(40)
|
(20)
|
-
|
20
|
40
|
60
|
80
|
100
|
120
|
KENVUE BAYER AG SANOFI PRIVATE LABEL HALEON
|
4W 13W 52W
|
Source: NielsenIQ, J.P. Morgan
|
This document is being provided for the exclusive use of DAVID WANG at MARLOWE PARTNERS LP.
|
65
|
Andrea Teixeira, CFA AC
|
(1-212) 622-6735
|
andrea.f.teixeira@jpmorgan.com
|
North America Equity Research
|
29 May 2023 J P M O R G A N
|
Cough & Cold. In the cold, cough (and allergy) remedies category as per Euromonitor
|
data globally, KVUE leads with market share of 7.3% followed by Haleon (6.7%) and
|
Reckitt (5.7%). We note here KVUEs global brands including Sudafed (0.7%) and
|
Benylin (0.6%) market share compared to competitors including Vicks (4.7%, owned by
|
OW-rated Procter & Gamble), Halls (3.4%, owned by Mondelez International) and
|
Mucinex (2.5%, owned by Reckitt), among others.
|
Figure 100: Cold & Cough Global Market Share by Company
|
6.7%
|
7.3%
|
7.5%
|
6.7%
|
5.1%
|
4.6% 5.7%
|
4.5% 5.0%
|
4.6% 4.6%
|
4.5%
|
3.6%
|
3.5%
|
0.0%
|
1.0%
|
2.0%
|
3.0%
|
4.0%
|
5.0%
|
6.0%
|
7.0%
|
8.0%
|
2013 2014 2015 2016 2017 2018 2019 2020 2021 2022
|
Kenvue Haleon Reckitt Procter & Gamble Bayer Sanofi Mondelez
|
Source: Euromonitor, J.P. Morgan
|
This document is being provided for the exclusive use of DAVID WANG at MARLOWE PARTNERS LP.
|
66
|
Andrea Teixeira, CFA AC
|
(1-212) 622-6735
|
andrea.f.teixeira@jpmorgan.com
|
North America Equity Research
|
29 May 2023 J P M O R G A N
|
Figure 101: Cold & Cough Global Market Share by Brands
|
4.7%
|
3.4%
|
2.5%
|
1.6%
|
0.7%
|
1.5%
|
1.0%
|
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.